These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 7222399)
1. [Surgical and combined treatment of kidney cancer]. Kliucharev BV; Kuz'min VG Vestn Khir Im I I Grek; 1980 Dec; 125(12):76-9. PubMed ID: 7222399 [TBL] [Abstract][Full Text] [Related]
2. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737 [TBL] [Abstract][Full Text] [Related]
3. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402 [TBL] [Abstract][Full Text] [Related]
5. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Belldegrun A; Shvarts O; Figlin RA Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666 [TBL] [Abstract][Full Text] [Related]
6. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275 [TBL] [Abstract][Full Text] [Related]
7. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Mitchell C; Pritchard-Jones K; Shannon R; Hutton C; Stevens S; Machin D; Imeson J; Kelsey A; Vujanic GM; Gornall P; Walker J; Taylor R; Sartori P; Hale J; Levitt G; Messahel B; Middleton H; Grundy R; Pritchard J; Eur J Cancer; 2006 Oct; 42(15):2554-62. PubMed ID: 16904312 [TBL] [Abstract][Full Text] [Related]
8. [Induction chemotherapy and larynx preservation: is such practice useful?]. Sarini J; Bocciolini C; Fournier C; Penel N; Kara A; Van JT; Lefebvre JL Bull Cancer; 2002 Apr; 89(4):411-7. PubMed ID: 12016041 [TBL] [Abstract][Full Text] [Related]
9. [Management of patients with kidney cancer without distant metastases]. Mavrichev AS; Krasnyĭ SA; Sukonko OG; Poliakov SL; Panov OV Urol Nefrol (Mosk); 1995; (6):6-10. PubMed ID: 8686131 [TBL] [Abstract][Full Text] [Related]
10. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Kuczyk M; Wegener G; Jonas U Eur Urol; 2005 Aug; 48(2):252-7. PubMed ID: 15936136 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of advanced Wilms' tumor]. Li MJ; Huang Y; Tang DX; Zhou YB; Tang HF; Liang JF Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):791-5. PubMed ID: 17366799 [TBL] [Abstract][Full Text] [Related]
12. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma? Kwak C; Park YH; Jeong CW; Lee SE; Ku JH Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297 [TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group. Kalapurakal JA; Nan B; Norkool P; Coppes M; Perlman E; Beckwith B; Ritchey M; Breslow N; Grundy P; D'angio GJ; Green DM; Thomas PR Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1379-84. PubMed ID: 15590168 [TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334 [TBL] [Abstract][Full Text] [Related]
16. [Results of combined therapy of malignant renal tumours (author's transl)]. Mau S; Riessbeck KH; Mandel L; Coblenz R Radiobiol Radiother (Berl); 1980; 21(3):271-83. PubMed ID: 7455011 [No Abstract] [Full Text] [Related]
17. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105 [TBL] [Abstract][Full Text] [Related]